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Control of Leishmania Major Infection in a Mouse Model of
Cutaneous Leishmaniasis
 
A murine model of cutaneous
leishmaniasis, using needle inoculation of 
 
Leishmania major,
 
represents perhaps the most widely used system to study the
contrasting effects of Th1 versus Th2 immunity in disease
control. One of the intriguing aspects of this disease model
is that certain strains of mice, such as BALB/c and SWR/J,
fail to control infection leading to progressive lesion devel-
opment and systemic infection, whereas the majority of
other mouse strains control infection at the local site of in-
oculation. Most humans infected with 
 
L. major
 
 manifest
with self-healing lesions limited to the skin. Thus, the sus-
ceptible strains of mice represent an abnormal situation
seen in rare patients who succumb to systemic infection
with the cutaneous 
 
Leishmania
 
 species. The susceptibility of
BALB/c mice to 
 
L. major
 
 is a multigenic phenomenon (1)
in which both the T cell and the non-T cell compartments
are impaired (2). It is generally accepted that a predominant
IL-4 response is associated with disease progression whereas
an IL-12/IFN-
 
 
 
–mediated Th1 response is associated with
lesion resolution and control of parasite spread. However,
recent evidence suggests that a transient Th2 response oc-
curs in both resistant and susceptible strains of mice (3), but
a sustained Th2 response is required for the development
and progression of disease (for a review, see reference 4).
Of importance in this regard are the abilities of the APCs in
redirecting the early Th2 response toward a protective Th1
response. Two papers published in this issue by Filippi et al.
(5) and by von Stebut and colleagues (6) address whether
DCs and the factors secreted by these cells contribute to the
susceptible versus resistant phenotypes after intradermal
(i.d.) 
 
L. major
 
 challenge, and point to a selective role for the
CD11b
 
hi
 
 subset of DCs in this process (5).
 
Identification of a Subset of Cutaneous DCs that Present
Leishmania Antigens In Vivo.
 
At the site of parasite inoc-
ulation, a number of distinct potential APCs are present
including epidermal Langerhans cells, dermal DCs, and
dermal macrophages. Within the epidermal layer are the
Langerhans cells that are characterized by their unique in-
tracellular organelles known as the Birbeck granules in
which the Langerin molecule is expressed (7, 8). In re-
sponse to stimulation, Langerhans cells emigrate in in-
creased numbers from the epidermis to the draining LNs.
This process is accompanied by the increase in their expres-
sion of CD40 and MHC class II molecules (9–13). Within
the LNs, these Langerhans cells can be distinguished from
other DC types as CD11b
 
mod
 
/CD8
 
 
 
lo
 
/CD11c
 
 
 
/CD205
 
hi
 
/
CD40
 
hi
 
/MHC class II
 
hi
 
/Langerin
 
 
 
 cells. Beneath the base-
ment membrane, a relatively understudied population of
DCs known as dermal DCs is present. These cells express
CD11c, CD11b (9–12, 14), and a variety of lectins includ-
ing MMGL (15) and in humans, DC-SIGN (16–19). Af-
ter migration into LNs, they increase in cell size and be-
come CD11b
 
hi
 
/CD8
 
 
 
 
 
/CD11c
 
 
 
/CD205
 
mod
 
/CD40
 
hi
 
/MHC
class II
 
hi
 
 (9–13). This population is likely distinct from the
CD14
 
 
 
 dermal Langerhans cell precursors that has been
identified (20) as the dermal DCs are negative for CD14
and lack Birbeck granules (14). Upon invasion by microbial
pathogens, however, the composition of DCs at the site of
infection may change dramatically from that of the steady
state. Assault by a pathogen triggers an inflammatory re-
sponse, resulting in the release of various cytokines and
chemokines. These inflammatory chemokines can mediate
the recruitment of leukocytes including DCs to the site of
infection, whereby enhancing the chances for DCs to
capture pathogens. Blood-derived DCs that migrate into
peripheral and lymphoid tissues express CD11b and low
levels of MHC class II (9, 11, 13, 21, 22). Thus, upon infec-
tion with 
 
L. major
 
, Langerhans cells, dermal DCs, dermal
macrophages, and blood-derived DCs may all contribute to
the presentation of parasite antigens to CD4
 
 
 
 T cells in the
draining LNs.
One of the key questions in this field has been, “which
cell type initiates protective immunity to 
 
L. major”
 
? Al-
though dermal macrophages are the primary cells infected
with 
 
L. major
 
, these cells are unlikely to participate in the
generation of CD4
 
 
 
 T cell immunity for the following rea-
sons: (a) dermal macrophages do not become activated as a
result of infection with promastigotes or amastigotes (23–
26), (b) their ability to secrete Th1-promoting cytokines is
suppressed (23–26), and (c) infected macrophages do not
migrate to the draining LNs where encounter with naive
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CD4
 
 
 
 T cells can be initiated. In contrast, a role for
Langerhans cells in the immune induction to 
 
L. major
 
 has
been described. 4 d after intradermal injection of 
 
L. major
 
promastigotes, CD205
 
 
 
 DCs containing the parasites were
found to appear within the draining LNs and present anti-
gens to CD4
 
 
 
 T cells (27). Although Langerhans cells ex-
press the highest levels of CD205 in the LNs, one cannot
rule out the possibility that the CD205
 
 
 
 cells in this study
included the dermal DCs, as they can express moderate
levels of CD205 in the LNs (9). Another support for the
role of Langerhans cells in CD4
 
 
 
 T cell priming comes
from a study of CCR2 deficient mice (28). These mice
have a defect in Langerhans cell migration in response to
FITC painting, and also have a defective anti-parasitic re-
sponse after i.d. injection of 
 
L. major
 
 promastigotes. These
two events may or may not be related, however, as distri-
bution and migration of other types of DCs are also abnor-
mal in these mice (28, 29).
The role of dermal DCs in 
 
L. major
 
 antigen presenta-
tion has been unclear until now. In the study by Filippi et
al. (5), by using a CD4
 
 
 
 T cell hybridoma specific for the
LACK peptide 158–163 bound to I-A
 
d
 
, the unique capac-
ity of the CD11b
 
 
 
, but not CD11b
 
 
 
, DCs in presenting
the LACK antigen to CD4
 
 
 
 T cells was demonstrated.
Moreover, using naive CD4
 
 
 
 LACK-specific TCR trans-
genic T cells, the CD11b
 
 
 
 DCs isolated from 2d 
 
L. ma-
jor
 
–infected susceptible strains of mice were shown to in-
duce Th2 differentiation while those from resistant strains
induced Th1 differentiation ex vivo (5). These results re-
vealed that there is an intrinsic difference in the ability of
the CD11b
 
 
 
 DCs to differentiate CD4
 
 
 
 T cells depend-
ing on the strains of mice from which they were isolated,
and that this difference correlates with the T cell pheno-
types that develop following 
 
L. major
 
 infection in the re-
spective mouse strains. Although the tissue origin of the
antigen-presenting CD11b
 
 
 
 DCs was not examined,
these CD11b
 
 
 
 DCs likely represent the dermal DCs, as
they are CD11b
 
 
 
/CD8
 
 
 
 
 
/CD11c
 
 
 
/CD40
 
hi
 
/MHC class
II
 
hi
 
 (5). To better identify these cells as dermal DCs, and
rule out Langerhans cells, however, the expression levels
for CD205, Langerin, and epithelial cell adhesion mole-
cule (Ep-CAM)-1 need to be examined as Langerhans
cells express high levels of these three markers (7–13, 30).
Alternatively, these CD11b
 
 
 
 DCs may represent blood
monocyte-derived DCs that have captured 
 
L. major
 
 anti-
gens in the dermis and migrated to the LNs. However,
monocyte-derived DCs are CD11c
 
dim
 
 (31) and would
have been excluded from the CD11c
 
 
 
 cells used by Fil-
ippi et al. (5). The importance of the CD11b
 
 
 
 DCs in
CD4
 
 
 
 T cell priming was also demonstrated in a recent
study by Itano and colleagues (32). By generating a re-
combinant protein consisting of a fusion between the
peptide 45–75 from the I-E molecule with a red fluores-
cence protein, they were able to follow both the anti-
gen itself (red fluorescence) and the presentation of the
I-Ep45–75 peptide bound to I-A
 
b
 
 (using the Y-Ae anti-
body that recognizes this complex). Using this clever sys-
tem, the antigen presentation in the draining LNs was found
to occur in two distinct waves. The first wave occurred
within the first 4–8 h, which resulted in the proliferation
of antigen-specific T cells in the draining LN. The second
wave of antigen presentation occurred around 24 h,
which induced T cell activation in the draining LNs. In-
terestingly, the second wave of antigen presentation was
required for the generation of functional T cell immunity
(as measured by DTH), and this response was mediated by
the CD11b
 
 
 
 DCs migrating from the dermis into the
draining LNs. Thus, in the case of 
 
L. major
 
 infection,
the time course of the CD11b
 
 
 
 DCs found to present the
LACK antigen to T cells in the draining LNs (48 h; refer-
ence 5) likely reflects the migration of antigen-loaded
dermal DCs to the draining LN corresponding to the
“second wave” of antigen presentation described by Itano
et al. (32).
The immunological relevance of the dermal CD11b
 
 
 
DCs during infection with pathogenic microbes needs to
be further examined. In this regard, the submucosal DCs,
which are the mucosal equivalent of the dermal DCs that
express similar markers, have been shown to play a domi-
nant role in Th1 induction after genital infection with her-
pes simplex virus type 2 (HSV-2; reference 33). Within
the vaginal mucosa, the replication of the virus occurred
exclusively in the vaginal epithelium, beneath which the
submucosal DCs were found to accumulate within the first
24 h. Subsequently, by 48 h, the CD11b
 
 
 
 DCs that have
captured viral antigens have migrated to the draining LNs
and began presenting viral antigens to CD4
 
 
 
 T cells (33).
Surprisingly, Langerhans cells in the LNs did not present
viral antigens to CD4
 
 
 
 T cells after vaginal HSV-2 infec-
tion. At other portals of pathogen entry, the subepithelial
CD11b
 
 
 
 DCs may possess a unique capacity to mediate
tissue-appropriate immune responses. For instance, in the
small intestine, CD11b
 
 
 
 DCs are found beneath the folli-
cle-associated epithelial cells in the Peyer’s patches (34,
35). In the absence of pathogens, these CD11b
 
 
 
 DCs re-
main in the subepithelial dome regions and secrete high
levels of IL-10 to promote Th2 differentiation ex vivo
(35–37). Upon microbial stimulation in vivo, the CD11b
 
 
 
DCs up-regulate CCR7 and migrate toward the T cell re-
gions (35), presumably to activate naive T cells. Taken to-
gether, data from Filippi et al. (5) and others (32, 33, 35)
all point toward the importance of the CD11b
 
 
 
 DCs in
capturing antigen in the dermis or submucosa, migrating to
the draining LNs and activating CD4
 
 
 
 T cells in a produc-
tive fashion (Fig. 1). One obvious question that arises from
these studies is “what do Langerhans cells do”? Recent ev-
idence suggests that Langerhans cells continually migrate
from the skin to the LNs in the absence of pathogen-
induced maturation (38, 39). Whether these cells contribute
to the immune initiation process for 
 
Leishmania
 
 and other
pathogens needs to be further explored. Moreover, as these
dermal/submucosal DCs express distinct set of pathogen-
recognition molecules (15–19) compared with the Langer-
hans cells (7, 8), their role in the capture and presentation
of bacterial, parasitic, and viral pathogens must be carefully
examined in vivo.T
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What Really Happens during Natural Infection with L. ma-
jor?
 
Although the study by Filippi et al. provided the long
awaited answer to the question, “what cells present 
 
L. major
 
antigens to CD4
 
 
 
 T cells in vivo”?, there are important
questions that still remain with regards to what happens af-
ter transmission of 
 
L. major
 
 in humans. 
 
Leishmania
 
 spp. are
transmitted through the bite of an infected sandfly vector,
 
Phlebotomus paratasi
 
, which inoculates a small number (100–
1,000) of metacyclic promastigotes into the skin (40). The
natural route of infection by the sandfly is accompanied by
the inoculation of salivary secretion, which has been shown
to exacerbate the lesion development at the site of infection
(24). Further, compared with the widely-used subcutane-
ous inoculation of 10
 
5
 
–10
 
7
 
 promastigotes, the inoculation
of the physiological number of promastigotes (100–1,000)
into dermal sites induces a very different disease course in
mice, which consists of a “silent” phase in which no T cell
responses are generated for the first 4–5 wk while parasites
replicate in the skin macrophages (41). This silent phase is
followed by the development of a lesion associated with
acute inflammation and reduction in the parasite number
peaking around 6 wk after infection. Therefore, in keeping
with the results from studies using 100–1,000 promasti-
gotes (41), the immune induction in humans infected by
sandflies may only begin after an incubation time, at the
end of which amastigotes are release from rupturing dermal
macrophages. Either the dying macrophages containing
amastigotes or the amastigotes themselves can be ingested
by the dermal DCs. This results in the infection, activation
and migration of dermal DCs to the draining LNs where
they can present the parasite antigens to CD4
 
 
 
 T cells (Fig.
1). In the study by Filippi et al., presentation of the LACK
antigen by the CD11b
 
 
 
 DCs at 48 h after injection pre-
sumably occurred in the absence of productive infection of
these DCs as 
 
L. major
 
 promastigotes have been shown not
to infect skin resident DCs in vitro (23) and in vivo (41).
Thus, it is likely that in their study (5), the dermal CD11b
 
 
 
DCs phagocytosed 
 
L. major
 
 promastigotes without becom-
ing infected, migrated, and presented the LACK antigen to
CD4
 
 
 
 T cells in the draining LNs. Therefore, during a nat-
ural course of infection with a sandfly vector, the question
of whether dermal DCs at the site of inoculation take up
metacyclic promastigotes (early) and/or amastigotes re-
leased from the macrophages (late) and migrate to the
draining LNs and activate CD4
 
 
 
 T cell responses must be
revisited using smaller inocula, with or without salivary se-
cretion from the sandfly.
 
The Role of IL-1
 
 
 
 and IL-1
 
 
 
 in the Generation of Protective
Immunity to Leishmania major.
 
The two papers published
in this issue both examined the possibility that the nature of
the DCs contribute to the susceptible versus resistant phe-
notype. Remarkably, upon examination of the cytokines
released from DCs either in vitro (6) or ex vivo (5), both
groups ended up identifying the members of the IL-1 cyto-
kine to be synthesized at higher levels in DCs from the re-
sistant strains compared with those from the susceptible
strains. The IL-1 system consists of two distinct ligands, IL-
1
 
 
 
 and IL-1
 
 
 
, both of which bind to the same receptor,
IL-1R type I (IL-1RI). Both types of IL-1 are made as pre-
cursor cytokines, and require processing by the proteases
calpain (for IL-1
 
 
 
) or caspase-1 (for IL-1
 
 
 
) to be cleaved
Figure 1. A proposed mechanism of CD4  T cell priming after Leish-
mania major infection. Infectious metacyclic promastigotes are introduced
into the dermis of the host by the bite of a sandfly or through needle in-
oculation. The promastigotes are taken up by skin dermal macrophages,
within which the parasite can replicate in the form of amastigotes.
Amastigotes released from ruptured macrophages can infect nearby der-
mal DCs, which results in the activation of dermal DCs and release of fac-
tors such as IL-1 and IL-12. In the case of needle injection of a large
number of promastigotes (105–107), the promastigotes can be taken up by
the dermal DCs and processed for MHC class II presentation. Either the
amastigote-infected dermal DCs (following sandfly bite) or promastigote-
loaded dermal DCs (after needle injection of  105 parasite) migrate to the
draining LNs and enter the T cell area to present parasite antigens to
CD4  T cells in the context of MHC class II (reference 5). Langerhans
cells infected with the parasite may also migrate to the draining LNs but
whether they present parasite antigens and induce CD4  T cell activation
needs to be further elucidated. IL-1 secreted from the DCs promotes Th1
differentiation of the antigen-specific T cells in several mutually nonex-
clusive ways: (a) IL-1 may facilitate the migration of dermal DCs from the
site of infection to the draining LNs (reference 44), (b) IL-1 may induce
activation of DCs through signaling of their IL-1RI/IL-1RAcP complex
via the MyD88 pathway, and (c) IL-1 may directly activate CD4  T cells
leading to their Th1 differentiation. Signaling of IL-1RI on DCs may
lead to increase in the expression levels of costimulatory molecules and
release of cytokines such as IL-12 and IL-18. Alternatively, a separate mi-
crobial stimulus present on Leishmania parasite may trigger the secretion
of IL-12, which is enhanced by the concomitant IL-1 signaling. In the re-
sistant strains, this IL-1 production from DCs is optimal, leading to the
activation of CD4  T cells to secrete IFN-  (references 5 and 6). In con-
trast, IL-1 secretion from DCs is reduced in the susceptible strains, leading
to suboptimal DC activation and Th2 differentiation (references 5 and 6).
Factors other than IL-1 likely also contribute to the intrinsic differences
between the CD11b  DCs of the susceptible and the resistant strains,
such as differences in the expression of costimulatory molecules (reference
5), other cytokines, chemokine/chemokine receptors, and perhaps TLRs.T
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into their active forms. The mature forms of IL-1
 
 
 
 and IL-
1
 
 
 
 have multiple effects in vivo as revealed by the analysis
of mice deficient for various components of the IL-1 sys-
tem (for a review, see reference 42). Upon binding of ei-
ther IL-1
 
 
 
 or IL-1  to IL-1RI, the IL-1RI forms a het-
erodimeric receptor complex with the IL-1R accessory
protein (IL-1RAcP) resulting in signal transduction. The
cytoplasmic domains of the IL-1RI and IL-IRAcP contain
the Toll-like receptor (TLR)/IL-1 (TIR) domain, which
upon activation recruits the MyD88 adaptor protein, lead-
ing to further activation of a signaling cascade involving
IRAK and TRAF-6.
It is intriguing that the two reports demonstrate prefer-
entially enhanced production of IL-1  (6) or IL-1  (5) by
the DCs from the resistant strains of mice. Each study
found exclusive role for either IL-1  but not IL-1  (6) or
vice versa (5). This discrepancy may relate to the differ-
ences in their experimental approaches. Specifically, Filippi
et al. used ex vivo CD11b  DCs isolated from the draining
LNs of 2 d L. major infected B10.D2 mice and found that
IL-1 , but not IL-1  mRNA, was expressed at 10- to 15-
fold higher levels compared with the CD11b  DCs of the
infected BALB/c mice (5). On the other hand, von Stebut
et al. used C57BL/6 fetal skin-derived DCs stimulated in
vitro with amastigotes and demonstrated that they ex-
pressed 1.7-fold higher IL-1  mRNA and 3–4-fold higher
IL-1  protein compared with those from BALB/c mice
(6). The results from these two studies suggest that in the
susceptible BALB/c mice, the ability of the DCs to secrete
IL-1 is reduced (5, 6), resulting in the failure to generate
Th1 responses to L. major. On the other hand, in resistant
C57BL/6 and B10.D2 strains, the DCs secrete higher levels
of IL-1, allowing efficient induction of Th1 responses in
vivo. To provide support for this hypothesis, both groups
tested the ability of IL-1 injection in the control of L. major
infection in the susceptible host, and convincingly demon-
strated that the recombinant IL-1  (6) or IL-1  (5) inocu-
lated around the time of L. major challenge enhanced pro-
tective immunity. However, a definitive proof that the
levels of IL-1 secreted from the DCs dictate the susceptibil-
ity of mouse strains is yet to be provided. Future studies
must examine the definitive importance of IL-1 secreted by
DCs in the generation of the protective immunity to L.
major challenge by using conditional knockout mice that
specifically lack the IL-1 genes in DCs, or by the adoptive
transfer of IL-1 /  DCs into IL-1 /  host.
The in vivo importance of IL-1 in anti-Leishmania im-
munity has been demonstrated in a previous study in which
IL-1RI–deficient mice infected with L. major promasti-
gotes were found to harbor higher parasite burden and in-
creased Th2 cytokine secretion in the draining LNs (43).
The IL-1 secreted during L. major infection can have an ef-
fect on both the T cells and the APCs. The importance of
IL-1 in DC migration (44), activation, and acquisition of
Th1-inducing ability has been demonstrated (45). On the
other hand, IL-1  has been shown to have a direct effect
on T cells, serving as a cofactor for IL-12–induced Th1 dif-
ferentiation for BALB/c but not C57BL/6 T cells (46). In
the study by von Stebut et al., the timing at which the in-
jection of recombinant IL-1  optimally enhanced protec-
tive immunity to L. major was determined to coincide with
that of CD4  T cell priming in vivo (6). Taken together,
these results lead to the hypothesis that IL-1  and IL-1 
secreted by the DCs at the time of CD4  T cell priming in
the draining LNs promote the generation of a protective
Th1 immunity through activating DCs and/or T cells via
the IL-1RI/MyD88-pathway (Fig. 1). Of interest in this
regard is the recent demonstration that MyD88-deficient
C57BL/6 mice failed to develop Th1 responses and control
lesion after i.d. L. major inoculation (47). The immune re-
sponses generated following L. major infection in MyD88 / 
and IL-1RI /  mice share the heightened Th2 responses
and parasite burden, but differ in that only the latter was
able to control lesion size (43, 47). Thus, a MyD88-depen-
dent pathway distinct from the IL-1RI must be involved in
the full activation of protective immunity in the resistant
mouse strains.
Future Vaccine Design and Implications. The current
studies highlight the importance of the DCs in the estab-
lishment of protective Th1 immunity in the draining LNs
(5, 6). Whether IL-1 secretion from the relevant DCs ac-
counts for the resistance to L. major infection or not, the
benefit of IL-1 injection at the time of parasite challenge
was clearly demonstrated in both studies (5, 6). A number
of vaccine strategies have been designed and tested in an ef-
fort to prevent disease in susceptible mice to high dose
challenge with live L. major. Now that we understand the
DC population responsible for presenting the parasite anti-
gens and inducing protective Th1 immunity in the resistant
strains, namely the CD11b  DCs, we can begin to design
vaccine approaches that target these DCs in the dermis. As
IL-12 was necessary for the injected IL-1  to mediate its
protective effects in vivo (6), an optimal vaccine to L. major
must ultimately result in DC activation and IL-12 secre-
tion. The best-known agents that accomplish these ends are
the TLR ligands. Further, a sustained IL-12 secreting envi-
ronment with persistent antigen presence has been shown
to be important in maintaining an effective immunity
against L. major (48). Given these constraints, it is not sur-
prising that plasmid DNA vaccines encoding L. major pro-
teins are effective in providing long lived protection in sus-
ceptible mice (48–52), as bacterial DNA can both trigger
TLR9 (DC activation) and provide a source of immuno-
gen through its prolonged expression in vivo. Future vac-
cine strategies may include the use of bicistronic plasmid
DNA vaccines in which both the Leishmania antigen and
the mature forms of the IL-1  or IL-1  are expressed, or
the injection of L. major antigens with recombinant IL-1 in
conjunction with an adjuvant that activates the TLR path-
way in the susceptible hosts.
I wish to thank C. Dela Cruz and R. Medzhitev for helpful discus-
sions.
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